Jun 05, 2020
Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma
May 01, 2020
Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma
Nov 28, 2019
Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China
Oct 01, 2019
Sosei Heptares Notes the Announcement of Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma
Jul 08, 2019
4D pharma plc Commences Phase I/II Asthma Trial
May 23, 2019
Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency
May 18, 2019
Mylan Presents Equivalence and Device Usability Data on Wixela(TM) Inhub(TM) Compared to Advair Diskus® at American Thoracic Society International Conference
Apr 29, 2019
Visiongain Report Looks at Opportunities Within the $46bn Asthma & COPD Therapies Market
Mar 28, 2019
Global COPD Drugs Market is projected to display robust growth represented by a CAGR of 2.47% during 2018 - 2023
Mar 27, 2019
Global COPD Drugs Market by Drug Type, Pipeline Drugs, Region, and Country - Forecast to 2023
Feb 12, 2019
Mylan Launches Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP), the First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder), at a List Price 70% Less than the Brand
Jan 31, 2019
Mylan Announces FDA Approval of Wixela(TM) Inhub(TM) (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder)
Nov 12, 2018
Theravance Biopharma Highlights Expanded COPD Indication for Trelegy Ellipta in Europe
Oct 11, 2018
Theravance Biopharma and Mylan Report Positive New Data from Multiple Studies of YUPELRI(TM) (revefenacin) at the 2018 CHEST Annual Meeting
Oct 11, 2018
FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
Sep 24, 2018
Theravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe
Sep 07, 2018
Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
Apr 25, 2018
Theravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients
Apr 19, 2018
Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients
Mar 29, 2018
New Large-Scale Trial Results Show Stiolto® Respimat® Prevents COPD Exacerbations Better Than Spiriva® Respimat®